AstraZeneca (AZN) Competitors

AstraZeneca logo
£140.34 +52.00 (+0.37%)
As of 12:37 PM Eastern

AZN vs. BMK, GSK, DPH, HIK, and INDV

Should you buy AstraZeneca stock or one of its competitors? AstraZeneca's main competitors and comparable companies include Benchmark (BMK), GSK (GSK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does AstraZeneca compare to Benchmark?

AstraZeneca (LON:AZN) and Benchmark (LON:BMK) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, AstraZeneca had 7 more articles in the media than Benchmark. MarketBeat recorded 7 mentions for AstraZeneca and 0 mentions for Benchmark. AstraZeneca's average media sentiment score of 0.40 beat Benchmark's score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media.

Company Overall Sentiment
AstraZeneca Neutral
Benchmark Neutral

AstraZeneca presently has a consensus price target of £155.50, indicating a potential upside of 11.31%. Given AstraZeneca's stronger consensus rating and higher possible upside, equities research analysts clearly believe AstraZeneca is more favorable than Benchmark.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Benchmark
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£62.38B3.47£8.71B£706.0019.79
Benchmark£79.16M1,189.43-£39.55M£0.06246,774.19

AstraZeneca has a beta of 0.212, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Benchmark has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 13.3% of Benchmark shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 63.7% of Benchmark shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AstraZeneca has a net margin of 17.69% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 22.31% beat Benchmark's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.69% 22.31% 7.68%
Benchmark -43.67%-15.96%-1.07%

Summary

AstraZeneca beats Benchmark on 12 of the 16 factors compared between the two stocks.

How does AstraZeneca compare to GSK?

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

GSK pays an annual dividend of GBX 68 per share and has a dividend yield of 3.5%. AstraZeneca pays an annual dividend of GBX 322.05 per share and has a dividend yield of 2.3%. GSK pays out 63.6% of its earnings in the form of a dividend. AstraZeneca pays out 45.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK£33.54B2.29£2.50B£106.9017.96
AstraZeneca£62.38B3.47£8.71B£706.0019.79

56.9% of GSK shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 0.2% of GSK shares are owned by company insiders. Comparatively, 0.2% of AstraZeneca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GSK has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.212, indicating that its share price is 79% less volatile than the broader market.

AstraZeneca has a net margin of 17.69% compared to GSK's net margin of 12.97%. GSK's return on equity of 24.64% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK12.97% 24.64% 9.56%
AstraZeneca 17.69%22.31%7.68%

GSK currently has a consensus price target of GBX 2,145, suggesting a potential upside of 11.72%. AstraZeneca has a consensus price target of £155.50, suggesting a potential upside of 11.31%. Given GSK's higher probable upside, research analysts plainly believe GSK is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 8 mentions for GSK and 7 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.40 beat GSK's score of 0.37 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
AstraZeneca
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

AstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Dechra Pharmaceuticals?

AstraZeneca (LON:AZN) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

AstraZeneca has a beta of 0.212, indicating that its share price is 79% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, AstraZeneca had 7 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 7 mentions for AstraZeneca and 0 mentions for Dechra Pharmaceuticals. AstraZeneca's average media sentiment score of 0.40 beat Dechra Pharmaceuticals' score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media.

Company Overall Sentiment
AstraZeneca Neutral
Dechra Pharmaceuticals Neutral

AstraZeneca has a net margin of 17.69% compared to Dechra Pharmaceuticals' net margin of -3.66%. AstraZeneca's return on equity of 22.31% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.69% 22.31% 7.68%
Dechra Pharmaceuticals -3.66%-3.92%0.75%

AstraZeneca has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£62.38B3.47£8.71B£706.0019.79
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A

AstraZeneca pays an annual dividend of GBX 322.05 per share and has a dividend yield of 2.3%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. AstraZeneca pays out 45.6% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca presently has a consensus price target of £155.50, suggesting a potential upside of 11.31%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities research analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Dechra Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AstraZeneca beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Hikma Pharmaceuticals has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.212, meaning that its share price is 79% less volatile than the broader market.

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,986.25, indicating a potential upside of 19.08%. AstraZeneca has a consensus target price of £155.50, indicating a potential upside of 11.31%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Hikma Pharmaceuticals is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 4.9%. AstraZeneca pays an annual dividend of GBX 322.05 per share and has a dividend yield of 2.3%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. AstraZeneca pays out 45.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than AstraZeneca. MarketBeat recorded 8 mentions for Hikma Pharmaceuticals and 7 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.40 beat Hikma Pharmaceuticals' score of -0.11 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AstraZeneca
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

AstraZeneca has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.42B1.01£353.21M£176.009.48
AstraZeneca£62.38B3.47£8.71B£706.0019.79

AstraZeneca has a net margin of 17.69% compared to Hikma Pharmaceuticals' net margin of 11.31%. AstraZeneca's return on equity of 22.31% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals11.31% 15.05% 9.40%
AstraZeneca 17.69%22.31%7.68%

Summary

AstraZeneca beats Hikma Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

Indivior (LON:INDV) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

86.0% of Indivior shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 3.4% of Indivior shares are held by company insiders. Comparatively, 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
AstraZeneca£62.38B3.47£8.71B£706.0019.79

AstraZeneca has a net margin of 17.69% compared to Indivior's net margin of 0.17%. AstraZeneca's return on equity of 22.31% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior0.17% -1.11% 2.37%
AstraZeneca 17.69%22.31%7.68%

Indivior has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.212, suggesting that its share price is 79% less volatile than the broader market.

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays an annual dividend of GBX 322.05 per share and has a dividend yield of 2.3%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. AstraZeneca pays out 45.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, AstraZeneca had 7 more articles in the media than Indivior. MarketBeat recorded 7 mentions for AstraZeneca and 0 mentions for Indivior. AstraZeneca's average media sentiment score of 0.40 beat Indivior's score of 0.00 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Overall Sentiment
Indivior Neutral
AstraZeneca Neutral

AstraZeneca has a consensus target price of £155.50, suggesting a potential upside of 11.31%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

AstraZeneca beats Indivior on 15 of the 18 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£217.66B£13.76B£7.83B£2.84B
Dividend Yield1.72%2.58%2.47%5.11%
P/E Ratio19.8829.0734.3423.37
Price / Sales3.497.758.005.05
Price / Cash38.8915.7421.0220.23
Price / Book5.345.194.762.51
Net Income£8.71B£2.88B£3.52B£5.88B
7 Day Performance-0.23%-3.87%-5.34%-0.01%
1 Month Performance12.76%-3.96%-3.61%-2.15%
1 Year Performance3.83%-7.13%0.01%7.21%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
4.0125 of 5 stars
£140.34
+0.4%
£155.50
+10.8%
+3.4%£217.66B£62.38B19.8896,100
BMK
Benchmark
N/A£153
-0.6%
N/A+0.0%£94.15B£79.16M246,774.19823
GSK
GSK
3.6642 of 5 stars
GBX 1,911.50
+0.6%
GBX 2,145
+12.2%
+7.5%£76.63B£33.54B17.8866,841
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
HIK
Hikma Pharmaceuticals
3.2686 of 5 stars
GBX 1,635
-0.9%
GBX 1,986.25
+21.5%
+3.2%£3.38B£3.42B9.299,500

Related Companies and Tools


This page (LON:AZN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners